Table 2.
Baseline characteristics of included studies comparing survivors and non-survivors of COVID-19 patients
| First Author | Study Location | Groups | Sample (N) |
Male % | Age (years) Mean ± SD / Median (IQR) | DM N (%) |
HT N (%) |
CVD N (%) |
NLR value Mean ± SD / Median (IQR) | NOS Score |
|---|---|---|---|---|---|---|---|---|---|---|
| Liu Y et al | China | NLR Tertile 1 (0.54–2.21) | 82 | 29 | 48 ± 16 | 5 (6) | 11 (13) | 5 (6) | NR | 8 |
| NLR Tertile 2 (2.21–4.82) | 81 | 49 | 53 ± 17 | 6 (7) | 14 (17) | 3 (4) | NR | |||
| NLR Tertile 3 (4.85–88.09) | 82 | 61 | 61 ± 15 | 12 (15) | 27 (33) | 10 (12) | NR | |||
| Chen R et al | China | Survivor | 445 | 55 | 54 ± 14 | 41 (9) | 103 (23) | 24 (5) | 3.71 (2.27–7.54) | 9 |
| Non-survivor | 103 | 67 | 67 ± 12 | 20 (19) | 45 (44) | 11 (11) | 13.45 (9.33–23.60) | |||
| Huang J et al | China | Survivor | 283 | 53 | 53 ± 17 | 31 (11) | 63 (22) | 14 (5) | 3.3 ± 4.3 | 8 |
| Non-survivor | 16 | 69 | 69 ± 10 | 4 (25) | 11 (69) | 4 (25) | 13.3 ± 14.3 | |||
| Zhang N et al | China | Survivor | 50 | 72 | 63 ± 11 | 5 (10) | 18 (36) | 11 (22) | 8.4 ± 7.5 | 6 |
| Non-survivor | 10 | 70 | 71 ± 9 | 4 (40) | 4 (40) | 3 (30) | 18.7 ± 16.6 | |||
| Li L et al | China | Survivor | 68 | 38 | 44 ± 13 | 6 (9) | 0 (0) | 0 (0) | 2.3 (1.6–3.8) | 7 |
| Non-survivor | 25 | 60 | 69 ± 11 | 5 (20) | 5 (20) | 4 (16) | 3.8 (2.8–6.6) | |||
| Luo X et al | China | Survivor | 214 | 46 | 51 (37–63) | 27 (13) | 37 (17) | 13 (6) | 2.96 (2.13–4.61) | 8 |
| Non-survivor | 84 | 61 | 71 (64–80) | 18 (21) | 49 (58) | 13 (16) | 8.17 (6.15–10.90) | |||
| Yan X et al | China | Survivor | 964 | 48 | 62 (50–70) | 97 (11) | 215 (22) | 65 (7) | 4.11 (2.44–8.12) | 8 |
| Non-survivor | 40 | 68 | 68 (58–79) | 10 (25) | 20 (50) | 10 (25) | 49.06 (25.71–69.70) | |||
| Chen L et al | China | Survivor | 1651 | 47 | 57 (43–66) | 203 (12) | 475 (29) | 205 (12)$ | 3 (2–4) | 9 |
| Non-survivor | 208 | 74 | 70 (63–78) | 59 (28) | 104 (50) | 62 (30)$ | 11 (6–20) | |||
| Tatum D et al | USA | NLR ≤ 4.94 | 62 | 43 | 56.1 ± 15.2 | NR | NR | NR | NR | 6 |
| NLR > 4.94 | 57 | 47 | 62.1 ± 14.1 | NR | NR | NR | NR | |||
| Ullah W et al | USA | NLR < 10 | 141 | 47 | 63.6 | 49 (35) | 93 (66) | 27 (19) | NR | 8 |
| NLR > 11 | 26 | 62 | 61.6 | 10 (39) | 14 (54) | 2 (8) | NR | |||
| Ye W et al | China | Survivor | 297 | 46 | 60 (50–67) | 41 (14) | 73 (25) | 5 (2) | 2.88 (1.79–6.74) | 8 |
| Non-survivor | 52 | 69 | 69 (63–76) | 16 (31) | 30 (58) | 11 (21) | 14.96 (8.52–26.58) | |||
| Yang Q et al | China | Survivor | 176 | 47 | 50 ± 15 | 28 (16) | 47 (27) | 6 (3) | 2.98 (1.70–5.51) | 8 |
| Non-survivor | 50 | 62 | 68 ± 16 | 17 (34) | 37 (74) | 7 (14) | 6.18 (3.58–12.78) | |||
| Zhang S et al | China | Survivor | 420 | 51 | 59 (48–67) | 60 (14) | 107 (26) | 53 (13) | 3.91 (2.07–6.79) | 7 |
| Non-survivor | 96 | 75 | 67 (61–74) | 16 (17) | 31 (32) | 14 (15) | 10.99 (7.68–20.97) | |||
| Cheng B et al | China | Survivor | 67 | 33 | 71 ± 7 | 11 (16) | 39 (58) | 11 (16) | 4.1 ± 2.9 | 8 |
| Non-survivor | 51 | 61 | 73 ± 7 | 16 (31) | 25 (49) | 12 (24) | 13.3 ± 14.9 | |||
| Chen C et al | China | Survivor | 119 | 56 | NR | 42 (35) | 80 (68) | 24 (20) | 4.19 (2.30–7.39) | 8 |
| Non-survivor | 13 | 69 | NR | 3 (23) | 10 (77) | 7 (54) | 12.21 (3.66–14.98) |
CVD = Cardiovascular Disease; DM = Diabetes Mellitus; HT = Hypertension; IQR = Interquartile Range; NLR = Neutrophil-to-lymphocyte ratio; NOS = Newcastle-Ottawa Scale; NR = Not Reported; SD = Standard Deviation; USA = United States of America; $ = included cerebrovascular disease.